Summary:
- Study Drug- Aducanumab is a unique, anti-AB monoclonal antibody
- Age 50 to 85
- Need Positive PET scan
- MMSE 24-30
- CDR score of 0.5
- Need caregiver- can do assessments by phone
- Must be MRI compatible
- All cholinesterase inhibitors and/or memantine allowed
- 18 month study
- 2 year open label extension
- Monthly infusions
- $75 Stipend for both Subject and Caregiver
Qualified Participants Must:
• Be between 50 and 85 years of age
•
Have a caregiver - can do assessments by phone
•
Be MRI compatible
Qualified Participants May Receive:
Monthly Infusions
$75 Stipend for both Subject and Caregiver
To learn more about this study visit the study website at https://www.aducanumabclinicaltrials.com/about-these-studies